A relatively new year, new guidelines, and new tools for prostate cancer screening and monitoring.
In recent months, the AUA updated its 2023 guidelines specifically for early detection of prostate cancer (https://www.auanet.org/guidelines-and-quality/guidelines/early-detection-of-prostate-cancer-guideline). Along with those guidelines, two other organizations have updated or developed additional tools that are beneficial to all men, regardless of where they are on the prostate cancer journey (or even those not yet on a journey).
The National Comprehensive Cancer Center Network (NCCN) posted its 2026 “Guidelines for Patients” pamphlet for early-stage prostate cancer (https://www.nccn.org/patients/guidelines/content/PDF/prostate-early-patient.pdf). Additionally, our friends at ASPI (https://aspatients.org/) have produced a pamphlet primarily focused on active surveillance: The Pathway: Your Guide to Active Surveillance, also reviewed by Howard Wolinsky ( https://howardwolinsky.substack.com/p/review-of-aspis-the-pathway-navigating )
Consider them collectively as an introduction to screening (NCCN), an AS-focused source (ASPI), and a comprehensive guide for early-stage prostate cancer.
I would not consider any of them as a standalone product for all the information a man might need. The NCCN guidelines are focused on screening and are relatively basic. ASPI’s product is focused on AS, but some may find the scope and scale of information a bit overwhelming without someone to advise and assist them. The appendix at the end of the pamphlet would be exceedingly useful for anyone beginning their prostate cancer journey. Finally, the AUA guidelines are broader and developed more for urologists.
–Dan Gifford (dan@ancan.org)